uniQure to Announce 2025 Financial Results
Rhea-AI Summary
uniQure (NASDAQ: QURE) will report fourth-quarter and full-year 2025 financial results before market open on Monday, March 2, 2026. Management will host a live conference call at 8:00 a.m. ET the same day.
The event will be webcast via the company’s Events & Presentations page and a replay will be archived for 90 days. Analysts may join the live Q&A by phone using conference ID 4607289; attendees are asked to dial in 15 minutes early.
Positive
- None.
Negative
- None.
News Market Reaction – QURE
In the Feb 23 session, QURE gained 4.42%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.2% during that session. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings date notice | Neutral | +5.6% | Set timing for Q3 2025 results and investor conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The single prior earnings-date announcement over the last six months was followed by a positive one-day move of 5.56%.
Over the past several months, uniQure has combined clinical progress with active regulatory dialogue and capital activity. A prior earnings-date announcement on Nov 06, 2025 preceded Q3 2025 results and coincided with a 5.56% one-day gain. Since then, the company has reported mixed regulatory signals for AMT-130 and raised substantial capital, while advancing programs like AMT-191. Today’s notice schedules the release of Q4 and full-year 2025 results, continuing its pattern of pre-announcing earnings calls.
AI-generated analysis. How Rhea-AI works. Not financial advice.
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 4607289. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Contacts:
| FOR INVESTORS: | FOR MEDIA: |
| Chiara Russo | Tom Malone |
| Direct: 781-491-4371 | Direct: 339-970-7558 |
| Mobile: 617-306-9137 | Mobile:339-223-8541 |
| c.russo@uniQure.com | t.malone@uniQure.com |
